Physician profile
Derek D Sun
NPI 1831267087
$4,318.38
in general payments reported to CMS, 2019-2025
23 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $292 · 2021: $935 · 2022: $742 · 2023: $594 · 2024: $519 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,035.07 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $772.49 | 2019-2025 | |
| Amgen INC. | $548.64 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $505.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.13 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $249.15 | 2019-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $165.57 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2019-2020 | |
| Lilly USA, LLC | $60.83 | 2020-2025 | |
| Heartflow, INC. | $58.84 | 2025 | |
| Nestle Healthcare Nutrition INC. | $56.20 | 2021 | |
| Esperion Therapeutics, INC. | $53.14 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $45.74 | 2023 | Inpefa |
| Alnylam Pharmaceuticals INC. | $33.50 | 2025 | Amvuttra |
| Abbott Laboratories | $24.96 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.45 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $21.10 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2021 | |
| Genentech USA, INC. | $18.01 | 2020 | |
| Vistapharm, INC. | $14.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2020 | |
| Pfizer INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.